INTRODUCTION {#S1}
============

Metabolic reprogramming is a hallmark of cancer ([@R28]; [@R49]). Transformed and tumorigenic cells require increased deoxyribonucleotide synthesis to fuel the genome replication that sustains their unregulated cell cycle and proliferation. Therefore, it is likely that the cell cycle and nucleotide metabolism are linked. The cell cycle inhibitor p16 is a critical tumor suppressor that is lost as an early event in the progression from senescent benign lesions to cancer ([@R9]; [@R10]; [@R14]; [@R35]; [@R44]; [@R55]). Indeed, expression of p16 is low or null in approximately half of all human cancers ([@R40]). Although the loss of p16 is known to play a role in deregulating the cell cycle, whether the loss of p16 expression affects nucleotide metabolism is unknown.

Both increased expression of p16 ([@R54]) and decreased levels of deoxyribonucleotide triphosphates (dNTPs) ([@R3]; [@R43]) are characteristics of cellular senescence, a stable cell cycle arrest ([@R1], [@R2]; [@R20]; [@R29]; [@R63]). Activation of oncogenes such as BRAF^V600E^ induces senescence to suppress transformation and tumorigenesis (termed oncogene-induced senescence \[OIS\]) ([@R50]; [@R64]). Therefore, OIS is considered an important tumor suppressor mechanism *in vivo* ([@R13]; [@R44]). Increased dNTPs or loss of p16 bypasses OIS to allow for transformation and tumorigenesis ([@R3], [@R4]; [@R17]; [@R18]; [@R24]; [@R27]; [@R53]). Thus, we reasoned that these two processes may be interconnected. Here, we used senescence as a model to study the link between p16 and nucleotide metabolism. We demonstrate that the loss of p16 increases nucleotide synthesis through upregulation of mTORC1 activity.

RESULTS {#S2}
=======

p16 Knockdown Enhances Nucleotide Synthesis to Bypass Senescence {#S3}
----------------------------------------------------------------

To determine whether p16 loss affects nucleotide synthesis, we took advantage of our previously published model of dNTP-depletion-induced senescence by knocking down RRM2 ([@R3]). Knockdown of p16 in shRRM2 cells suppressed senescence markers ([Figures 1A](#F1){ref-type="fig"}--[1E](#F1){ref-type="fig"} and [S1A](#SD1){ref-type="supplementary-material"}). Data using a second independent hairpin targeting p16 and overexpression of p16 cDNA demonstrate that these results are p16 specific ([Figures S1B](#SD1){ref-type="supplementary-material"}--[S1K](#SD1){ref-type="supplementary-material"}). Knockdown of p16 in the pathologically relevant model of BRAF^V600E^-induced senescence also bypassed senescence ([Figures 1F](#F1){ref-type="fig"}--[1J](#F1){ref-type="fig"}). Knockdown of p16 in both models significantly increased deoxyribonucleotide di-phosphates (dNDPs)/dNTPs even above control levels in some nucleotides ([Figures 1K](#F1){ref-type="fig"} and [1L](#F1){ref-type="fig"}). Interestingly, we observed an increase in RRM2B in shRRM2/shp16 cells ([Figures S1L](#SD1){ref-type="supplementary-material"} and [S1M](#SD1){ref-type="supplementary-material"}), which is likely how these cells reduce nucleoside diphosphates and nucleoside triphosphates (NDPs/NTPs) to dNDPs/ dNTPs. Excitingly, further metabolite analysis demonstrated that nucleotides were also significantly increased upon p16 knockdown in these models ([Figures 1M](#F1){ref-type="fig"}, [1N](#F1){ref-type="fig"}, and [S1N](#SD1){ref-type="supplementary-material"}), suggesting that the increase in deoxyribonucleotides is not simply due to increased RRM2B or the proportion of cells in S phase. Together, these data indicate that p16 depletion increases both nucleotide and deoxyribonucleotide synthesis to bypass senescence.

p16 Knockdown Activates mTORC1 to Bypass Senescence and Increase Nucleotide Synthesis {#S4}
-------------------------------------------------------------------------------------

We next aimed to determine the underlying mechanism of nucleotide synthesis upon p16 knockdown. p16 inhibits E2F-mediated transcription in part through regulating the retinoblastoma protein (RB)-E2F interaction ([@R56]). Gene set enrichment analysis (GSEA) of our RNA sequencing (RNA-seq) (GEO: GSE133660) did not show terms related to nucleotide synthesis ([Data S1](#SD2){ref-type="supplementary-material"}). However, GSEA showed an enrichment in the mTORC1 signaling pathway upon p16 knockdown, which was confirmed by reverse phase protein array (RPPA) ([Data S1](#SD2){ref-type="supplementary-material"}). Underscoring the pathological relevance of our findings, the mTORC1 signaling pathway was also enriched in melanoma compared with nevi in two independent datasets ([@R33]; [@R58]) ([Data S1](#SD2){ref-type="supplementary-material"}). Previous studies demonstrated that mTORC1 increases nucleotide synthesis ([@R7], [@R8]), suggesting that this may be the mechanism by which the loss of p16 increases nucleotides. We confirmed the activation of mTORC1 signaling by assessing the increased phosphorylation of S6K and 4E-BP1 ([Figures 2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}) as well as by mTORC localization at the lysosomal membrane ([Figures S2A](#SD1){ref-type="supplementary-material"} and [S2B](#SD1){ref-type="supplementary-material"}). Inhibition of mTORC1 with temsirolimus significantly decreased nucleotides and deoxyribonucleotides and suppressed senescence bypass in both models ([Figures 2A](#F2){ref-type="fig"}--[2L](#F2){ref-type="fig"} and [Data S2](#SD3){ref-type="supplementary-material"}), whereas it had no effect on parental cell proliferation ([Figure S2C](#SD1){ref-type="supplementary-material"}). Together, these data demonstrate that activation of mTORC1 downstream of p16 loss drives the observed increase in nucleotides, which is required for senescence bypass.

mTORC1 is a master regulator of translation ([@R42]; [@R45]). Interestingly, increased expression of leading-edge genes associated with the ''translation'' GSEA term ([Data S1](#SD2){ref-type="supplementary-material"}) significantly co-occurred with alterations in *CDKN2A* in multiple cancer types and was associated with worse overall survival ([Figures S2D](#SD1){ref-type="supplementary-material"} and [S2E](#SD1){ref-type="supplementary-material"}). Additionally, knockdown of p16 in cancer cell lines with wild-type p16 expression increased phosphorylation of S6K and 4E-BP1 ([Figure 2M](#F2){ref-type="fig"}). Consistently, low p16 expression increased the sensitivity to mTORC1 inhibition ([Figures 2N](#F2){ref-type="fig"}, [S2F](#SD1){ref-type="supplementary-material"}, and [S2G](#SD1){ref-type="supplementary-material"}). Together, these data indicate that mTORC1 activation also occurs in cancer cells upon p16 suppression and correlates with increased sensitivity to mTORC1 inhibition.

Finally, we aimed to determine whether increased mTORC1 signaling is dependent on RB. Although RB knockdown suppressed BRAF^V600E^-induced senescence, it did not increase p-S6K or p-4EBP1 in any of the models tested ([Figures S2H](#SD1){ref-type="supplementary-material"}--[S2N](#SD1){ref-type="supplementary-material"}). Consistently, mTOR signaling pathways were not enriched in an independent dataset of RB knockdown in senescence ([Data S1](#SD2){ref-type="supplementary-material"}) ([@R16]). This suggests that the upregulation of mTORC1 activity is not a cell-cycle-dependent phenomenon and that it occurs in an RB-independent pathway. Together, these data demonstrate that activation of mTORC1 signaling upon p16 suppression is critical for nucleotide synthesis and senescence bypass in an RB-independent manner.

mTORC1 Activation by p16 Knockdown Increases Translation of Ribose-5-Phosphate Isomerase A and Promotes Nucleotide Synthesis through the Pentose Phosphate Pathway {#S5}
------------------------------------------------------------------------------------------------------------------------------------------------------------------

Previous reports showed that mTORC1 upregulates purine and pyrimidine metabolism through ATF4-*MTHFD2* and CAD, respectively ([@R7], [@R8]). We did not observe an increase in *MTHFD2* transcription or CAD phosphorylation after p16 knockdown ([Figures S3A](#SD1){ref-type="supplementary-material"} and [S3B](#SD1){ref-type="supplementary-material"}). As mTORC1 activity increases translation ([@R42]), we aimed to determine whether the observed increase in mTORC1-mediated nucleotide synthesis upon p16 suppression increases translation of transcripts involved in nucleotide synthesis. We performed polysome fractionation ([Figure S3C](#SD1){ref-type="supplementary-material"}) followed by RT-qPCR analysis of transcripts involved in nucleotide synthesis and related anaplerotic pathways. Our results reveal a number of transcripts whose abundance shifted from the light to the heavy polysome fraction upon p16 knockdown ([Figure 3A](#F3){ref-type="fig"}; [Table S1](#SD1){ref-type="supplementary-material"}), including *EEF2*, which is known to be translationally regulated by mTORC1 ([@R59]) ([Figure S3D](#SD1){ref-type="supplementary-material"}). Interestingly, ribose-5-phosphate isomerase A (*RPIA*), an enzyme that synthesizes the ribose sugar backbone for both purines and pyrimidines ([@R37]) was the top hit (see [STAR Methods](#S8){ref-type="sec"}) ([Figure 3A](#F3){ref-type="fig"}; [Table S1](#SD1){ref-type="supplementary-material"}). Although MYC increases *RPIA* transcription ([@R52]), we did not observe changes in *RPIA* gene expression or MYC protein expression in these cells ([Figures 3B](#F3){ref-type="fig"} and [S3E](#SD1){ref-type="supplementary-material"}). Consistent with the idea that mTORC1 regulates *RPIA* translation, RPIA protein expression was increased after p16 knockdown and decreased upon mTORC1 inhibition with temsirolimus ([Figures 3C](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}). Increased RPIA protein expression was also observed in 7 isogenic cancer cell lines upon p16 suppression ([Figures 3E](#F3){ref-type="fig"} and [3F](#F3){ref-type="fig"}) and decreased upon knockdown of RPTOR ([Figure S3F](#SD1){ref-type="supplementary-material"}). Inhibition of mTORC1 with temsirolimus shifted the *RPIA* mRNA from the heavy to the light polysome fraction, whereas it did not decrease total *RPIA* mRNA expression ([Figures 3G](#F3){ref-type="fig"} and [S3G](#SD1){ref-type="supplementary-material"}). To confirm the direct role of mTORC1 in *RPIA* translation upon p16 knockdown, we performed polysome fractionation after 3 h of Torin 1 treatment (similar to [@R59]). Torin 1 inhibited mTORC1 activity and *RPIA* translation ([Figures 3H](#F3){ref-type="fig"} and [3I](#F3){ref-type="fig"}). Additionally, knockdown of p16 increased 35S-methionine and cysteine incorporation into RPIA, which was decreased by Torin 1 treatment ([Figure 3J](#F3){ref-type="fig"}). Consistent with increased RPIA protein expression, total ribose-5-phosphate (R5P) was increased upon p16 knockdown and decreased by inhibition of mTORC1 ([Figures 3K](#F3){ref-type="fig"} and [3L](#F3){ref-type="fig"}). Finally, stable isotope labeling using U-^13^C glucose demonstrated an increase in the M+5 fraction of R5P and multiple nucleotides upon p16 knockdown, which was abrogated by temsirolimus treatment ([Figures 3M](#F3){ref-type="fig"}--[3P](#F3){ref-type="fig"}; [Data S2](#SD3){ref-type="supplementary-material"}). Taken together, these data demonstrate that knockdown of p16 increases mTORC1-mediated translation of *RPIA* to fuel R5P and nucleotide synthesis.

R5P Isomerase A Is a Metabolic Vulnerability of p16-Low Cells *In Vitro* and *In Vivo* {#S6}
--------------------------------------------------------------------------------------

To determine whether RPIA is necessary for proliferation of cells with p16 knockdown, we depleted RPIA by using two independent short hairpin RNAs (shRNAs). Our data indicate that RPIA is necessary for proliferation of p16 knockdown cells as it induced senescence in all cell models tested ([Figures 4A](#F4){ref-type="fig"}--[4I](#F4){ref-type="fig"}, [S4A](#SD1){ref-type="supplementary-material"}--[S4F](#SD1){ref-type="supplementary-material"}, and [S5A](#SD1){ref-type="supplementary-material"}--[S5F](#SD1){ref-type="supplementary-material"}). Knockdown of RPIA alone had no effect on parental cells ([Figures S4A](#SD1){ref-type="supplementary-material"}--[S4F](#SD1){ref-type="supplementary-material"}). We did not observe a marked increase in cell death ([Figure S5G](#SD1){ref-type="supplementary-material"}), suggesting that the observed loss of proliferation is likely due to the senescence-associated cell cycle arrest. Similar results were observed *in vivo*, where knockdown of RPIA inhibited tumor growth in HT-29 cells with shp16 but not controls ([Figures 4J](#F4){ref-type="fig"}--[4L](#F4){ref-type="fig"}). Consistent with our *in vitro* data, *LMNB1* was decreased only in shp16/shRPIA tumors ([Figure 4M](#F4){ref-type="fig"}). Although there was a decrease in *CCNA2* upon RPIA knockdown alone, the difference was significantly larger in shp16/shRPIA compared to shp16 alone tumors ([Figure 4N](#F4){ref-type="fig"}). Together, these data indicate that RPIA-mediated increased nucleotide synthesis is necessary for cancer cell proliferation both *in vitro* and *in vivo* and that suppression of RPIA may be a target for cancers with low p16 expression.

DISCUSSION {#S7}
==========

The absence of p16 predisposes cells to tumorigenesis ([@R38]), and its expression is low or null in many human cancers ([@R15]; [@R23]). There is currently no approved targeted therapy for p16-low tumors ([@R46]). Therefore, delineating the molecular mechanisms downstream of p16 suppression is critical to identify new therapeutics for these patients. Although the role of p16 loss in deregulating the cell cycle has been known for decades ([@R56]), its role in metabolism is unclear. In this study, we found that mTORC1 signaling activation upon p16 suppression increases nucleotide synthesis. Mechanistically, we found mTORC1 activity leads to increased translation of *RPIA* and glucose flux through the pentose phosphate pathway to increase nucleotide levels. Suppression of p16 in cancer cells also leads to increased mTORC1 activity and increased RPIA translation and protein expression, and these cells are more sensitive to mTORC1 inhibitors or RPIA suppression than p16 wild-type cells. Together, our results suggest that increased nucleotide metabolism by RPIA upregulation is a metabolic vulnerability of p16-null cancers.

Cancer cells reprogram metabolism to increase biomass needed for growth and proliferation ([@R49]). Modulation of nucleotide and deoxyribonucleotide levels is critical for multiple cancer cell phenotypes, including for the repair of damaged DNA and to ensure rapid proliferation ([@R34]). We previously found that increased dNTPs, either through upregulation of RRM2 expression or loss of ATM, bypass senescence ([@R3], [@R4]). Additionally, a recent paper found that metabolic reprogramming, including increased nucleotide levels, precedes tumor formation in a UVB-induced skin cancer model ([@R30]). Here, we show that the loss of p16 increases nucleotide synthesis through a mechanism mediated by mTORC1. Excitingly, activation of this pathway increased both nucleotides and deoxyribonucleotides. We observed an increase in the other ribonucleotide reductase R2 subunit RRM2B. RRM2B has been shown to play a role in mitochondrial dNTP synthesis and in response to DNA damage ([@R12]; [@R51]). Interestingly, RRM2B was increased in both shRRM2 alone and shRRM2/shp16 cells. This suggests that although RRM2B is likely important for reducing NDPs/NTPs to dNDPs/dNTPs in senescence bypass, its upregulation alone is not sufficient to produce dNDPs/dNTPs. Indeed, these data further support the notion that it is only when upstream nucleotides are also increased, such as when p16 is knocked down, that the expression of RRM2B is critical for senescence bypass.

The canonical function of p16 is upstream of RB to affect E2F and the cell cycle ([@R56]). We found that mTORC1 upregulation downstream of p16 knockdown is independent of RB in multiple cell types. There are an increasing number of studies reporting RB-independent functions of p16 ([@R6]; [@R32]; [@R39]; [@R61]), suggesting that the non-canonical pathway of p16 loss needs to be explored to identify both mechanistic underpinnings of RB-independent functions and novel therapies for cancer patients with p16-null tumors. As knockdown of p16 increased mTORC at the lysosomal membrane, it is possible that this pathway affects amino acid transporters and/or uptake. Additionally, a previous report in a mouse model of melanomagenesis also found increased mTORC1 signaling upon *Cdkn2a* knockout due to miR-99/100 expression ([@R17]). Finally, it is possible that the effect of p16 knockdown is through cyclin D1/CDK4, which has previously been shown to phosphorylate TSC2, thereby activating mTORC1 signaling ([@R25]). Further research is needed to understand the connection between the loss of p16 and the activation of mTORC1.

mTORC1 is a master regulator of metabolism by coordinating metabolite availability though translational control of metabolic enzymes ([@R31]; [@R67]). Recent studies have linked mTORC1 to both purine and pyrimidine synthesis ([@R7], [@R8]). Our results indicate that suppression of p16 increases mTORC1-mediated translation of *RPIA*. Previous studies have shown that *RPIA* is transcriptionally regulated by mTORC1 signaling ([@R21]) or MYC ([@R52]). We did not observe a transcriptional increase in *RPIA* or MYC upregulation in our model, suggesting that *RPIA* upregulation is context-dependent. Consistent with our results, a recent paper showed that total *RPIA* mRNA expression is not significantly decreased after 24 h of Torin 1 treatment ([@R48]). Instead, our data demonstrate that RPIA is directly translationally regulated by mTORC1 as inhibition of mTORC1 with a short Torin 1 treatment decreased *RPIA* transcripts in the heavy polysome fraction as well as RPIA protein expression. Consistent with the idea that our results are MYC-independent, a previous publication demonstrated that *MYC* mRNA is resistant to Torin 1 inhibition ([@R59]). Taken together, these data demonstrate that the observed increase in RPIA protein upon the loss of p16 is mediated though mTORC1-specific translation.

Cell cycle inhibitors are currently being tested in the clinic for tumors with deletions or mutations in *CDKN2A* (<http://clinicaltrials.gov>); however, no US Food and Drug Administration (FDA)-approved therapy currently exists for this subset of patients. Moreover, our data and others demonstrate that p16 may have functions outside of the cell cycle and RB ([@R6]; [@R32]; [@R39]; [@R61]), suggesting that these inhibitors may not be efficacious in these patients. Excitingly, our results with p16 suppression open up a metabolic vulnerability through activation of mTORC1-mediated nucleotide metabolism. Indeed, we found that isogenic p16-null cells are more sensitive to temsirolimus or suppression of RPIA both *in vitro* and *in vivo*. RPIA inhibition has been shown to limit the growth of Kras^G12D^ cell lines and xenografted tumors ([@R52]; [@R65]). Our results demonstrate that RPIA expression could also be exploited as a metabolic target in p16-null cancers.

In conclusion, our study provides a molecular effect of p16 loss whereby mTORC1 signaling is activated to increase nucleotide metabolism. This is different, yet likely linked, to its canonical role in cell cycle regulation. These mechanistic insights have broad implications for understanding pro-tumorigenic metabolism. Moreover, this study provides a metabolic vulnerability for p16-low cancer cells, which may be exploited for therapy.

STAR★METHODS {#S8}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S10}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Katherine M. Aird (<kaird@psu.edu>). There are restrictions to the availability of the shRNA knockdown cell lines generated in this study since they were made with commercial reagents. These will only be distributed with permission of the commercial suppliers.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S11}
--------------------------------------

### Cell Lines {#S12}

Normal diploid IMR90 human fibroblasts were cultured according to the ATCC in low oxygen (2% O~2~) in DMEM (4.5 g/L glucose, Corning cat\# 10-017-CV) with 10% FBS supplemented with L-glutamine, non-essential amino acids, sodium pyruvate, and sodium bicarbonate. Experiments were performed on IMR90 between population doubling \#25--35. Melanoma (SKMel28), pancreatic (PATU8902), colorectal (HT-29, SW620, and SW480) tumor cells and lentiviral and retroviral packaging cells (293FT and Phoenix, respectively) were cultured in DMEM (Corning, cat\# 10--013-CV) with 10% FBS. ES2 ovary tumor cell line was cultured in RPMI 1640 with 10% FBS. TCCSUP bladder cancer cell line was cultured in MEM/EBSS glutamine supplemented with 10% FBS. All cell lines were cultured in MycoZap and were routinely tested for mycoplasma as described in [@R62]. All tumor cell lines included in this work express wild-type *CDKN2A* according to TCGA ([@R15]; [@R23]). According to ATCC, TCCSUP harbors a mutation in RB1. All cell lines were authenticated using STR Profiling (Genetica DNA Laboratories).

### Mice {#S13}

Two-month old male SCID mice were purchased from Charles River Laboratories. All mice were maintained in a HEPA-filtered ventilated rack system at the Penn State College of Medicine animal facility. Mice were housed up to 5 mice per cage and in a 12-hour light/dark cycle. All experiments with animals were performed in accordance with institutional guidelines approved by the Institutional Animal Care and Use Committee (IACUC) at the Penn State College of Medicine.

METHOD DETAILS {#S14}
--------------

### Lentiviral and retroviral packaging and infection {#S15}

Retrovirus production and transduction were performed using the BBS/calcium chloride method ([@R3]). Phoenix cells (a gift from Dr. Gary Nolan, Stanford University) were used to package the infection viruses. Lentiviral constructs were transfected into 293FT cells using Lipofectamine 2000 (Thermo Fisher). Lentivirus was packaged using the ViraPower Kit (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions.

The basic IMR90 experiment timeline is delineated in [Figure S1A](#SD1){ref-type="supplementary-material"}. Briefly, IMR90 cells were infected with pLKO.1 empty vector or pLKO.1-shRRM2, and 24 hours later cells were infected with pLKO.1 empty vector, pLKO.1-shp16 or pLKO.1-shRB. Cells were selected with puromycin (3 µg/mL) for 7 days. Alternatively, IMR90 cells were infected with pBABE control or pBABE BRAF^V600E^ vector and 24 hours later cells were infected with a second round of pBABE control or BRAF^V600E^ vector together with pLKO.1 empty vector, pLKO.1-shp16 or pLKO.1-shRB. Cells were selected with puromycin (3 mg/mL) for 7 days. Where indicated, cells were treated at day 4 with temsirolimus (0.5nM) or infected with pLKO.1-shRPIA. p16 rescue experiment was performed by simultaneous infection with pLKO.1-shp16 and pBABE-p16 overexpression plasmid. For single infections, cells were infected with the corresponding virus and selected in puromycin (1 µg/mL) for 7 days.

Tumor cell lines were infected with pLKO.1 empty vector, pLKO.1-shp16 or pLKO.1-shRB. Cells were selected with puromycin (1 µg/mL) for 4 days. Where indicated, cells were treated at day 4 with increasing concentrations of temsirolimus (0.07--50 µM) in 0.5% FBS for 5 days or infected with pLKO.1 shRPIA or pLKO.1-shRPTOR. For double infections, cells were selected in puromycin (3 µg/mL) for 4 additional days. For Torin 1 experiments, cells were serum starved for 16h and then treated with 250nM Torin 1 for 3h in 0.5% FBS.

### RNA-Sequencing and Analysis {#S16}

Total RNA was extracted from cells at day 7 ([Figure S1A](#SD1){ref-type="supplementary-material"}) with Trizol (Life Technologies) and DNase treated with RNeasy Mini Kit (QIAGEN, cat\#74104) following the manufacturer's instructions. RNA integrity number (RIN) was measured using BioAnalyzer (Agilent Technologies) RNA 6000 Nano Kit to confirm RIN above 7 for each sample. The cDNA libraries were prepared using KAPA Stranded RNA-Seq Kits with RiboErase (Kapa Biosystems). Next generation sequencing was performed in The Penn State College of Medicine Genome Sciences and Bioinformatics Core facility as previously described in [@R41] using a HiSeq 2500 sequencer (Illumina). Demultiplexed and quality-filtered mRNA-Seq reads were then aligned to human reference genome (GRCh38) using TopHat (v.2.0.9). Differential expression analysis was done using Cuffdiff tool which is available by Cufflinks (v.2.0.2) as described in [@R41]. Three technical replicates were used. Raw counts and differential expression analysis generated during this study are available at GEO (GSE133660).

### Reverse Phase Protein Array (RPPA) {#S17}

After 7 days under selection ([Figure S1A](#SD1){ref-type="supplementary-material"}), cells cultured in 10cm dishes were incubated on ice with 300uL of lysis buffer (1% Triton X-100, 50mM HEPES pH = 7.5, 150mM NaCl, 1.5mM MgCl2, 1mM EGTA, 100mM NaF, 10mM Na pyrophosphate, 1mM Na3VO4 and 10% glycerol) for 20 min with occasional shaking every 5 min. After incubation, cells were scraped off the plate and centrifuged at 18000 g for 10 min at 4°C. Total protein was quantified with Bradford assay and 90ug of protein was diluted 3:1 in SDS sample buffer (40% glycerol, 8% SDS, 0.25M Tris-HCl and 10% B-mercaptoethanol). Lysates were boiled at 95°C for 5 min and stored at −80°C. RPPA data was generated and analyzed by the CCSG-supported RPPA Core Facility at the University of Texas MD Anderson Cancer Center ([@R5]). A total of 240 authenticated Antibodies for total protein expression and 64 antibodies for protein phosphorylation were analyzed in this study. The complete antibody list can be found in <https://www.mdanderson.org/research/research-resources/core-facilities/functional-proteomics-rppa-core.html>.

### Gene set enrichment analysis (GSEA) {#S18}

Expression values included in the Talantov dataset (18 nevi and 45 primary melanoma tumors) ([@R58]) were downloaded from GEO (GSE3189), while the expression values included in the Kabbarah dataset (9 nevi and 31 primary melanoma tumors) ([@R33]) were downloaded from GEO (GSE46517). Gene Cluster Text files (GTC), as well as Categorical Class files (CLS) were generated independently for, RPPA, Talantov and Kabbarah datasets following the Gene Set Enrichment Analysis (GSEA) documentation indications (<http://software.broadinstitute.org/gsea/index.jsp>). GTC and CLS files were used to run independent GSEA analysis (javaGSEA desktop application). GSEA for Hallmarks, KEGG and Reactome were run independently under the following parameters: 1000 permutations, weighted enrichment analysis, signal to noise metric for ranking genes, and ''meandiv'' normalization mode. Following GSEA documentation indications, terms with p value \< 0.05 and a q-value \< 0.25 were considered significant ([Data S1](#SD2){ref-type="supplementary-material"}). For both, the RNA-Seq performed in this work (GSE133660) and Chicas dataset ([@R16]) (GSE133660), genes were ranked according to the fold-change and p value obtained on the differential gene expression analysis as follows: --log10(p value)\*sign(log 2 fold change). Pre-ranked files were built up for the RNA-Seq and Chicas datasets and used to run pre-ranked GSEA ([@R57]) under predefined parameters following GSEA documentation indications.

### Polysome fractionation {#S19}

Eight culture plates per condition (\~23 million cells per condition) were incubated with harringtonine (2 µg/mL) for 2 min at 37°C followed by 5 min of cycloheximide (100 µg/mL) treatment at 37°C. Cells were washed twice with PBS after each treatment. Cells were scraped in 600uL of lysis buffer (50mM HEPES, 75mM KCl, 5mM MgCl2, 250mM sucrose, 0.1mg/mL cycloheximide, 2mM DTT, 1% Triton X-100, 1.3% sodium deoxycholate and 5 mL of RNase OUT) on ice. Lysates were rocked for 10 min at 4°C and centrifuged at 3000 g for 15 min at 4°C. 400 mL of lysates supernatant (cytosolic cell extracts) were layered over cold sucrose gradients (10mM HEPES, 75mM KCl, 5mM MgCl2, 0.5mM EDTA and increasing sucrose concentrations from 20% to 47%). Gradients were centrifuged at 34,000 rpms in a Beckman SW41 rotor for 2h and 40 min at 4°C. After centrifugation, light (0 to 2 ribosomes) and heavy (\< 2 ribosomes) polysome fractions were collected in Trizol (1:1) using a density gradient fractionation system (Brandel) equipped with a UA-6 absorbance detector and a R1 fraction collector.

### RT-qPCR {#S20}

Total RNA was extracted from cells with Trizol, DNase treated, cleaned, and concentrated using Zymo columns (Zymo Research, Cat\# R1013) following the manufacturer's instructions. Similarly, mRNA from polysome fractions was DNase treated, cleaned, and concentrated using Zymo columns. Total RNA from tumor samples was isolated with NucleoSpin RNA/Protein following manufacturer's instructions. Optical density values of RNA were measured using NanoDrop One (Thermo Scientific) to confirm an A260 and A280 ratio above 1.9. Relative expression of target genes (listed in [Table S2](#SD1){ref-type="supplementary-material"}) were analyzed using the QuantStudio 3 Real-Time PCR System (Thermo Fisher Scientific) with clear 96 well plates (Greiner Bio-One). Primers were designed using the Integrated DNA Technologies (IDT) tool (<https://eu.idtdna.com/scitools/Applications/RealTimePCR/>) ([Table S2](#SD1){ref-type="supplementary-material"}). A total of 25ng of RNA was used for One-Step qPCR (Quanta BioSciences) following the manufacturer's instructions in a final volume of 10ul. Conditions for amplification were: 10 min at 48°C, 5 min at 95°C, 40 cycles of 10 s at 95°C and 7 s at the corresponding annealing temperature ([Table S2](#SD1){ref-type="supplementary-material"}). The assay ended with a melting curve program: 15 s at 95°C, 1 min at 70°C, then ramping to 95°C while continuously monitoring fluorescence. Alternatively, relative expression of *CDKN2A* was determined by adapting the method of [@R66]. A total of 100ng of RNA was used for One-Step qPCR (Quanta BioSciences) flowing the manufacturer's instructions in a final volume of 10uL. Conditions for amplification were: 10 min at 48°C, 5 min at 95°C, 4 cycles of 10 s at 95°C and 10 s starting at 66°C and decreasing 2°C per cycle, 50 cycles of 10 s at 95°C and 7 s at 64°C. The assay ended with a melting curve program as above. Each sample was assessed in triplicate. Relative quantification was determined to multiple reference genes (*B2M*, *MRPL9*, *PSMC4*, and *PUM1*) using the delta-delta Ct method. The percentage of target gene mRNA in each polysome fraction was calculated as in [@R47], but Ct values were first normalized to reference genes.

### \[35S\]-methionine/cysteine incorporation followed by IP {#S21}

After 16h of FBS starvation, cells were treated with 250nM Torin 1 or DMSO in media supplemented with 0.5% FBS for 3h. Thirty minutes prior to the end of Torin 1 treatment, 110uCi \[35S\]-methionine/cysteine was added to each plate. Cells were wash twice with PBS and pelleted. The pellet was resuspended in 100uL of denaturing Lysis buffer (1mM SDS and 5mM EDTA pH = 8) and boiled at 95°C for 5 min. Lysates were resuspended in 900uL of non-denaturing buffer (20mM Tris-HCl pH = 8, 137mM NaCl, 1mM EDTA pH = 8 and 1% Triton-X), sonicated, and centrifuged (10 min, 13,000 g, 4°C). The supernatant was collected, and the protein concentration was determined using the Bradford assay. 500ug of protein per condition was precleared with 15uL of magnetic beads (rotating 1h, 4°C). 5uL per sample of anti-RPIA or anti-IgG were bound to magnetic beads (rotating 3h, 4°C). Precleared samples were incubated with corresponding magnetic beads with conjugated antibodies (rotating overnight, 4°C). Magnetic beads were washed 3 times for 15 min each at 4°C with cold wash buffer (10mM Tris-HCl pH = 7.4, 1mM EDTA pH = 8, 1mM EGTA pH = 8, 150mM NaCl, 1% Triton-X, 0.2mM Na~3~VO~4~, 1mM PMSF and cOmplete Mini EDTA-free 1X). Immunoprecipitates were eluted in 10uL of 1X sample buffer (2% SDS, 10% glycerol, 0.01% bromophenol blue, 62.5mM Tris, pH 6.8, and 0.1M DTT) and boiled 10 min at 65°C and 1000rpm. Immunoprecipitates and 10% of input were separated under a 12% acrylamide gel. Acrylamide gel was stained with Coomassie blue and immunoprecipitated bands corresponding to RPIA (35kDa) were excised from the gel. Excised bands were weighted for normalization purposes before digestion with 1mL of electrode buffer (96mM Tris, 500mM glycine and 0.4% w/s SDS) for 16h at 4°C. Excised band suspensions were used to quantify the counts per minute (CPM) in a Beckman LS6500 scintillation counter. CPMs were normalized to corresponding band weights (mg).

### Senescence and proliferation assays {#S22}

SA-β-Gal staining was performed as previously described ([@R19]). Cells were fixed in 2% formaldehyde/0.2% glutaraldehyde in PBS (5 min) and stained (40 mM Na~2~HPO~4~, 150 mM NaCl, 2 mM MgCl~2,~ 5 mM K~3~Fe(CN)~6~, 5 mM K~4~Fe(CN)~6~, and 1 mg/ml X-gal) overnight at 37°C in a non-CO~2~ incubator. Images were acquired at room temperature using an inverted microscope (Nikon Eclipse Ts2) with a 20X/0.40 objective (Nikon LWD) equipped with a camera (Nikon DS-Fi3). Each sample was assessed in triplicate and at least 100 cells per well were counted (\> 300 cells per experiment).

For BrdU incorporation, cells on coverslips were incubated with 1uM BrdU for 30 min (IMR90, ES2, and SKMel28) or 15 min (SW620, SW480, HT-29, PATU8902, and TCCSUP). Cells were fixed in 4% paraformaldehyde (10min), permeabilized in 0.2% Triton X-100 (5 min), and postfixed in 1% PF 0.01% Tween-20 (30 min). Cells were DNaseI treated (10 min) previous to blocking with 3% BSA/PBS (5 mins). Cells were incubated in anti-BrdU primary antibody in 3% BSA/PBS (1:500) for 1h followed by 3 washes using 1% Triton X-100. Cell were then incubated 1h in FITC anti-Rat secondary antibody in 3% BSA/PBS (1:1000). Finally, cells were incubated with 0.15 µg/ml DAPI in PBS (1 min), mounted, and sealed. Images were acquired at room temperature using a Nikon Eclipse 90i microscope with a 20x/0.17 objective (Nikon DIC N2 Plan Apo) equipped with a CoolSNAP Photometrics camera. Each sample was assessed in triplicate and at least 200 cells per well were counted (\> 600 cells per experiment).

For colony formation, an equal number of cells were seeded in 6-well plates and cultured for an additional 2 weeks. Colony formation was visualized by fixing cells in 1% paraformaldehyde (5 min) and staining with 0.05% crystal violet (20 min). Wells were destained in 500 µL 10% acetic acid (5 min). Absorbance (590nm) was measured using a spectrophotometer (Spectra Max 190). Each sample was assessed in triplicate.

### Temsirolimus half maximal inhibitory concentration (IC~50~) assay {#S23}

Twenty thousand cells per condition were plated in 12-well plates in triplicates. After 24 h regular media was replaced by 0.5% FBS supplemented media with increasing concentrations of temsirolimus (0uM, 0.07uM, 0.21uM, 0.62uM, 1.85uM, 5.56uM, 16.67uM and 50uM). After 5 days cells were fixed in 1% paraformaldehyde (5 min) and stained with 0.05% crystal violet (20 min). Wells were destained in 500uL 10% acetic acid (5 min). Absorbance (590nm) was measured using a spectrophotometer (Spectra Max 190). The half maximal inhibitory concentration (IC~50~) was defined as the concentration resulting in a 50% reduction in absorbance.

### Immunofluorescence {#S24}

Cells were fixed in 4% paraformaldehyde (10min) and permeabilized in 0.2% Triton X-100 (5 min). Cells were blocked with 3% BSA/ PBS (1h) and incubated in anti-mTORC (1/200) and anti-LAMP2 (1/100) in 3% BSA/PBS (16h) followed by 3 washes using 1% Triton X-100. Cells were then incubated in FITC anti-Rabbit (1/2000) and Cy3 anti-mouse (1/5000) secondary antibodies in 3% BSA/PBS (1 h). Finally, cells were incubated with 0.15 µg/ml DAPI in PBS (1 min), mounted and sealed. Images were acquired at room temperature using a confocal microscope (Leica SP8) with a 64X oil objective. Co-localization analysis was performed using the Leica software in a total of 14 cells per sample.

### Western blotting {#S25}

Cell lysates were collected in 1X sample buffer (2% SDS, 10% glycerol, 0.01% bromophenol blue, 62.5mM Tris, pH 6.8, 0.1M DTT) and boiled (10 min at 95°C). Protein concentration was determined using the Bradford assay. Proteins were resolved using SDS-PAGE gels and transferred to nitrocellulose membranes (Fisher Scientific) (110mA for 2 h at 4°C). Membranes were blocked with 4% BSA in TBS containing 0.1% Tween-20 (TBS-T) for 1 h at room temperature. Membranes were incubated overnight at 4°C in primary antibodies in 4% BSA/TBS 0.025% sodium azide. Membranes were washed 4 times in TBS-T for 5 min at room temperature after which they were incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. After washing 4 times in TBS-T for 5 min at room temperature, proteins were visualized on film after incubation with SuperSignal West Pico PLUS Chemiluminescent Substrate (ThermoFisher, Waltham, MA).

### Nucleotide Analysis by LC-HRMS {#S26}

LC-HRMS for nucleotides and other polar metabolites was as previously described ([@R26]; [@R36]). Briefly, an Ultimate 3000 UHPLC equipped with a refrigerated autosampler (at 6°C) and a column heater (at 55°C) with a HSS C18 column (2.1 × 100 mm i.d., 3.5 µm; Waters) was used for separations. Solvent A was 5 mM DIPEA and 200 mM HFIP and solvent B was methanol with 5 mM DIPEA 200 mM HFIP. The gradient was as follows: 100% A for 3 min at 0.18 mL/min, 100% A at 6 min with 0.2 mL/min, 98% A at 8 min with 0.2 mL/min, 86% A at 12 min with 0.2 mL/min, 40% A at 16 min and 1% A at 17.9 min-18.5 min with 0.3 mL/min then increased to 0.4 mL/min until 20 min. Flow was ramped down to 0.18 mL/min back to 100% A over a 5 min re-equilibration. For MS analysis, the UHPLC was coupled to a Q Exactive HF mass spectrometer (Thermo Scientific) equipped with a HESI II source operating in negative mode. The operating conditions were as follows: spray voltage 4000 V; vaporizer temperature 200°C; capillary temperature 350°C; S-lens 60; in-source CID 1.0 eV, resolution 60,000. The sheath gas (nitrogen) and auxiliary gas (nitrogen) pressures were 45 and 10 (arbitrary units), respectively. Single ion monitoring (SIM) windows were acquired around the \[M-H\]^-^ of each analyte with a 20 *m/z* isolation window, 4 *m/z* isolation window offset, 1e^6^ ACG target and 80 ms IT, alternating in a Full MS scan from 70--950 *m/z* with 1e6 ACG, and 100 ms IT. Data was analyzed in XCalibur v4.0 and/or Tracefinder v4.1 (Thermo Scientific) using a 5 ppm window for integration of the peak area of all analytes. Used standards for nucleotides and deoxinucleotides both isotope labeled and non-labeled are indicated on the table. No suitable source of stable isotope labeled ADP, dADP, dTDP, CDP, or dCDP was found, thus the mono-phosphate was used as a surrogate internal standard. Guanine nucleotides were not quantified due to spectral overlap with the highly abundant adenine nucleotides.

### Glucose labeling and analysis {#S27}

Cells were seeded in 10 cm culture plates and at the end of the indicated treatment ([Figure S1A](#SD1){ref-type="supplementary-material"}) cells were washed twice with PBS and incubated 8h in DMEM (Cat\# D5030) supplemented with 5mM of ^13^C~6~-D-glucose, 0.5% of charcoal stripped FBS and 20mM of HEPES. Isotopologue patterns for dNDPs, dNTPs, and ribose-5-phosphate were analyzed by LC-HRMS as indicated above. Adjustment for natural isotopic abundance was conducted through open source and publicly available FluxFix ([@R60]).

### Flow Cytometry {#S28}

For 7AAD staining both cells and media were collected and centrifuged (1000 rpm for 5 min) followed by resuspension in 500uL of 7AAD staining solution (5uL of 7AAD solution and 38mM NaCitrate). Stained cells were run on a 10-color FACSCanto flow cytometer (BD biosciences). Data were analyzed with FlowJo Software. Each sample was assessed in triplicate.

### Murine tumor model {#S29}

HT-29 colorectal carcinoma cells were infected with shRNA targeting p16 and RPIA alone or in combination. After 2 days of puromycin selection (3 µg/mL), 3 million cells were resuspended in 200 µL of PBS and injected subcutaneously into the left flank of SCID mice. Mice were monitored daily to identify palpable tumors. Mice weight and tumor length (L) and width (W) (L \> W) were measured every 3 days after a tumor volume of 200mm^3^. Tumor volume was calculated as 1/2 (L x W^2^). All animals were sacrificed at day 26 post injection and tumor tissues collected for following experiments. A total of 22 animals were used in this study (6 control, 6 shRPIA, 4 shp16 and 6 shp16/shRPIA).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S30}
---------------------------------------

GraphPad Prism version 7.0 was used to perform statistical analysis. The level of significance between two groups was assessed with unpaired t test. For dataset with more than two groups, one-way ANOVA followed by Tukey's post hoc test was applied. P values \< 0.05 were considered significant. The IC~50~ dose-response curves were plotted, and IC~50~ values calculated using the log(inhibitor) versus normalized response function in GraphPad Prism Version 7.0. Kaplan-Meier survival plots differences between the two groups were analyzed with log-rank (Mantel-Cox) test using GraphPad Prism version 7.0. Data for the indicated tumors was obtained from cBioportal ([@R15]; [@R23]). Unpaired t test between shRRM2/shp16 and shRRM2 alone was assessed with GraphPad Prism version 7.0 for each transcript included in the polysome fractionation experiment ([Figure 3A](#F3){ref-type="fig"}; [Table S1](#SD1){ref-type="supplementary-material"}). P values were adjusted according to Benjamini and Hochberg's false discovery rate (FDR) and the percentage of shift between the light and the heavy fraction in shRRM2/shp16 was calculated (% transcript in heavy fraction - % transcript in light fraction) for each transcript. Hits were defined as those transcripts that were significantly (FDR P-value \< 0.05) decreased in the light fraction and significantly (FDR P-value \< 0.05) increased in the heavy fraction in shRRM2/shp16 when compared with shRRM2 alone. With these criteria we narrowed the list to three transcripts: ribose-5-phosphate isomerase A (*RPIA*), nucleoside diphosphate kinase A (*NME1*), and nucleoside diphosphate kinase 3 (*NME3*). NME1/NME3 are known metastasis suppressors ([@R11]); therefore, we focused on *RPIA*. Longitudinal and cross-sectional analysis of tumor volume where calculated using TumorGrowth tool with default parameters ([@R22]).
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![Suppression of p16 Increases Nucleotide Synthesis to Bypass Senescence\
(A--E) IMR90 cells expressing shRNA targeting RRM2 (shRRM2) alone or in combination with an shRNA targeting p16 (shp16). One of 5 experiments is shown.\
(A) Immunoblot analysis of the indicated proteins.\
(B) Senescence-associated-β-galactosidase (SA-β-Gal) activity, bromodeoxyuridine (BrdU) incorporation, and colony formation (CF). One of 5 experiments is shown. Scale bar, 10 μm.\
(C) Quantification of SA-β-Gal activity in (B). n = 3/group; 1 of 5 experiments is shown. Data represent mean ± SD. \*p \< 0.001.\
(D) Quantification of BrdU incorporation in (B). n = 3/group; 1 of 5 experiments is shown. Data represent mean ± SEM. \*p \< 0.001.\
(E) Quantification of colony formation in (B). n = 3/group; 1 of 5 experiments is shown. Data represent mean ± SEM. \*p \< 0.001.\
(F--J) IMR90 cells expressing BRAF^V600E^ alone or in combination with an shRNA targeting p16 (shp16).\
(F) Immunoblot analysis of the indicated proteins. One of 3 experiments is shown.\
(G) SA-β-Gal activity, BrdU incorporation, and colony formation (CF). One of 5 experiments is shown. Scale bar, 10 µm.\
(H) Quantification of SA-β-Gal activity in (G). n = 3/group, 1 of 5 experiments is shown. Data represent mean ± SD. \*p \< 0.001.\
(I) Quantification of BrdU incorporation in (G). n = 3/group; 1 of 5 experiments is shown. Data represent mean ± SEM. \*p \< 0.002.\
(J) Quantification of colony formation in (G). n = 3/group; 1 of 5 experiments is shown. Data represent mean ± SEM. \*p \< 0.001.\
(K--N) Deoxyribonucleotide analysis in the RRM2 (K) and BRAF^V600E^ (L) models and ribonucleotide analysis in the RRM (M) and BRAF^V600E^ (N) models. n \> 3/group; 1 of at least 2 experiments is shown. Data represent mean ± SEM. \*p \< 0.05. NA, not available.\
See also [Figure S1](#SD1){ref-type="supplementary-material"} and [Data S1](#SD2){ref-type="supplementary-material"}.](nihms-1538192-f0002){#F1}

![Suppression of p16 Activates mTORC1 to Increase Nucleotide Synthesis\
(A) IMR90 cells expressing shRNA targeting RRM2 (shRRM2) alone or in combination with an shRNA targeting p16 (shp16) and treated with temsirolimus (Tem). Immunoblot analysis of the indicated proteins. One of 3 experiments is shown.\
(B) IMR90 cells expressing BRAF^V600E^ alone or in combination with an shRNA targeting p16 (shp16) and treated with temsirolimus (Tem). Immunoblot analysis of the indicated proteins. One of 3 experiments is shown.\
(C and D) Deoxyribonucleotide analysis in the RRM2 (C) and BRAF^V600E^ (D) models. n \> 3/group; 1 of at least 3 experiments is shown. Data represent mean ± SEM. \*p \< 0.05.\
(E) Same as (A). SA-β-Gal activity, BrdU incorporation, and colony formation (CF). One of 3 experiments is shown. Scale bar, 10 µm.\
(F) Quantification of SA-β-Gal activity in (E). n = 3/group; 1 of 3 experiments is shown. Data represent mean ± SEM. \*p \< 0.001.\
(G) Quantification of BrdU incorporation in (E). n = 3/group; 1 of 3 experiments is shown. Data represent mean ± SEM. \*p \< 0.001.\
(H) Quantification of colony formation in (E). n = 3/group; one of 3 experiments is shown. Data represent mean ± SEM. \*p \< 0.001.\
(I) Same as (B). SA-β-Gal activity, BrdU incorporation, and colony formation (CF). One of 3 experiments is shown. Scale bar, 10 μm.\
(J) Quantification of SA-β-Gal activity in (I). n = 3/group; 1 of 3 experiments is shown. Data represent mean ± SEM. \*p \< 0.02.\
(K) Quantification of BrdU incorporation in (I). n = 3/group, 1 of 3 experiments is shown. Data represent mean ± SEM. \*p \< 0.001.\
(L) Quantification of colony formation in (I). n = 3/group, 1 of 3 experiments is shown. Data represent mean ± SEM. \*p \< 0.001.\
(M) Immunoblot analysis of the indicated proteins in cancer cell lines with wild-type p16 expressing shp16. One of at least 2 experiments is shown.\
(N) Same as (M) but cells were treated with temsirolimus. n = 3/group; 1 of 2 experiments is shown.\
See also [Figure S2](#SD1){ref-type="supplementary-material"} and [Data S1](#SD2){ref-type="supplementary-material"} and [S2](#SD3){ref-type="supplementary-material"}.](nihms-1538192-f0003){#F2}

![Suppression of p16 Increases mTORC1-Mediated *RPIA* Translation and Nucleotide Synthesis by the Pentose Phosphate Pathway\
(A and B) IMR90 cells expressing shRNA targeting RRM2 (shRRM2) alone or in combination with an shRNA targeting p16 (shp16).\
(A) Heatmap of light and heavy fractions from polysome profiling (see [Table S1](#SD1){ref-type="supplementary-material"} for raw data). This experiment was performed once with 3 technical replicates.\
(B) Total *RPIA* expression from RNA-seq. Data represent mean ± SEM. ns, not significant.\
(C) Same as (A) but cells were treated with temsirolimus (Tem). Immunoblot analysis of the indicated proteins. One of 3 experiments is shown.\
(D) IMR90 cells expressing BRAF^V600E^ alone or in combination with shp16 and treated with temsirolimus (Tem). Immunoblot analysis of the indicated proteins. One of 3 experiments is shown.\
(E) *CDKN2A* expression in the indicated cancer cell lines with wild-type p16 expression expressing shp16. \*p \< 0.006.\
(F) Same as (E) but immunoblot analysis of RPIA. One of at least 2 experiments is shown.\
(G) Percentage of *RPIA* mRNA abundance in polysome fractions in the indicated conditions. \*p \< 0.05.\
(H--J) SKMel28 and HT-29 cell expressing shp16 treated with Torin 1.\
(H) Immunoblot analysis of the indicated proteins.\
(I) Percentage of *RPIA* mRNA abundance in polysome fractions.\
(J) Counts per million (CPM) after \[35S\]-methionine and cysteine labeling and RPIA immunoprecipitation (IP). Data represent the percentage of CPM normalized by the excised band weight. One of 2 experiments is shown.\
(K and L) Ribose-5-phosphate (R5P) abundance in the RRM2 (K) and BRAF^V600E^ (L) models. n \> 3/group; 1 of at least 3 experiments is shown. Data represent mean ± SEM. \*p \< 0.01.\
(M and N) R5P M+5 in the RRM2 (M) and BRAF^V600E^ (N) models. n \> 3/group; 1 of at least 3 experiments is shown. Data represent mean ± SEM. \*p \< 0.05.\
(O and P) dTTP M+5 and UTP M+5 in the RRM2 (O) and BRAF^V600E^ (P) models. n \> 3/group; 1 of at least 3 experiments is shown. Data represent mean ± SEM. \*p \< 0.03; ND, not detected.\
See also [Figure S3](#SD1){ref-type="supplementary-material"}, [Data S2](#SD3){ref-type="supplementary-material"}, and [Table S1](#SD1){ref-type="supplementary-material"}.](nihms-1538192-f0004){#F3}

![Inhibition of RPIA Is a Metabolic Vulnerability for Cells with Low p16\
(A--E) IMR90 cells expressing BRAF^V600E^ alone or in combination with 2 independent shRNAs targeting RPIA (shRPIA).\
(A) Immunoblot analysis of the indicated proteins. One of 3 experiments is shown.\
(B) SA-β-Gal activity, BrdU incorporation, and colony formation. One of 3 experiments is shown. Scale bar, 10 μm.\
(C) Quantification of SA-β-Gal activity in (B). n = 3/group; 1 of 3 experiments is shown. Data represent mean ± SEM. \*p \< 0.001.\
(D) Quantification of BrdU incorporation in (B). n = 3/group; 1 of 3 experiments is shown. Data represent mean ± SEM. \*p \< 0.02.\
(E) Quantification of colony formation in (B). n = 3/group; 1 of 3 experiments is shown. Data represent mean ± SEM. \*p \< 0.001.\
(F--H) ES2 (F), HT-29 (G), and PATU8902 (H) cancer cell lines with wild-type p16 expression expressing shRPIA alone or in combination with shp16. SA-b-Gal activity, BrdU incorporation, and colony formation (CF). n = 3/group; 1 of at least 2 experiments is shown. Scale bar, 10 mm. Data represent mean ± SEM. \*p \< 0.05 versus shp16 alone.\
(I) *CCNA2* and *LMNB1* fold change in the indicated cells. One of at least 2 experiments is shown. Data represent mean ± SD. \*p \< 0.05 versus shp16 alone.\
(J) Tumor growth curve of the indicated groups.\
(K) Representative images of mice from each group. Tumors are outlined in red.\
(L) Tumor volume at day 26 post-implantation. \*p = 0.0414; ns, not significant.\
(M) *LMNB1* expression in the indicated tumors. ns, not significant.\
(N) *CCNA2* expression in the indicated tumors.\
See also [Figures S4](#SD1){ref-type="supplementary-material"} and [S5](#SD1){ref-type="supplementary-material"}.](nihms-1538192-f0005){#F4}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                               SOURCE                        IDENTIFIER
  --------------------------------------------------------------------------------- ----------------------------- -------------------------------------
  Antibodies                                                                                                      
                                                                                                                  
  RRM2                                                                              Santa Cruz Biotechnology      Cat \# sc-398294
  p16                                                                               Abcam                         Cat\# ab108349; RRID:AB_10858268
  Vinculin                                                                          Sigma-Aldrich                 Cat\# V9131; RRID:AB_477629
  S6K                                                                               Cell Signaling Technology     Cat\# 2708; RRID:AB_390722
  Phospho S6K (Thr389)                                                              Cell Signaling Technology     Cat\# 9234; RRID:AB_2269803
  4E-BP1                                                                            Cell Signaling Technology     Cat\# 9644; RRID: AB_2097841
  Phospho 4E-BP1 (Ser65)                                                            Cell Signaling Technology     Cat\# 9451; RRID: AB_330947
  RPTOR                                                                             Cell Signaling Technology     Cat\# 2280; RRID: AB_561245
  β-Actin                                                                           Sigma-Aldrich                 Cat\# A1978; RRID:AB_476692
  RPIA                                                                              Abcam                         Cat\# ab181235
  BRAF                                                                              Santa Cruz Biotechnology      Cat\# sc-5284; RRID:AB_2721130
  RB                                                                                BD Biosciences                Cat\# 554136; RRID:AB_39525
  CAD                                                                               Cell Signaling Technology     Cat\# 11933; RRID: AB_2797772
  Phospho CAD (Ser1859)                                                             Cell Signaling Technology     Cat \# 70307; RRID: AB_2799782
  BrdU                                                                              Abcam                         Cat\# ab6326; RRID:AB_305426
  mTOR                                                                              Cell Signaling Technology     Cat\# 2983; RRID:AB_2105622
  LAMP2                                                                             Santa Cruz Biotechnology      Cat\# sc-18822; RRID:AB_626858
  Anti-mouse HRP                                                                    Cell Signaling Technology     Cat\# 7076; RRID:AB_330924
  Anti-rabbit HRP                                                                   Cell Signaling Technology     Cat\# 7074; RRID:AB_2099233
  Anti-rat FITC                                                                     Jackson ImmunoResearch Labs   Cat\# 712--095-150; RRID:AB_2340651
  Anti-rabbit FITC                                                                  Jackson ImmunoResearch Labs   Cat\# 711--095-152; RRID:AB_2315776
  Anti-mouse Cy3                                                                    Jackson ImmunoResearch Labs   Cat\# 715--165-150; RRID:AB_2340813
                                                                                                                  
  Bacterial and Virus Strains                                                                                     
                                                                                                                  
  Stbl3 Chemically Competent E.                                                     Fisher Scientific             Cat\# C737303
  DH5α Competent Cells                                                              Fisher Scientific             Cat\# 18265--017
                                                                                                                  
  Chemicals, Peptides, and Recombinant Proteins                                                                   
                                                                                                                  
  BrdU                                                                              Alfa Aesar                    Cat \# H27260
  \[35S\]-methionine/cysteine                                                       Perkin Elmer                  Cat \# NEG772
  X-Gal                                                                             Sigma-Aldrich                 Cat \# B4252
  D-Glucose-13C6                                                                    Sigma-Aldrich                 Cat \# 389374
  Puromycin                                                                         GIBCO                         Cat \# A11138--02
  Polybrene                                                                         Sigma-Aldrich                 Cat \# H9268
  Propidium Iodide                                                                  Sigma-Aldrich                 Cat\# P4170
  PureProteome™ Protein G Magnetic Beads                                            EMD Millipore                 Cat \# LSKMAGG10
  cOmplete Mini EDTA-free                                                           Roche                         Cat \# 11836170001
  Crystal violet                                                                    Harleco                       Cat \# 192--12
  DMEM 17                                                                           Corning                       Cat\# 10--017-CV
  DMEM 13                                                                           Corning                       Cat\# 10--013-CV
  RPMI                                                                              GIBCO                         Cat\# 11875093
  DMEM w/o glucose or glutamine                                                     Sigma-Aldrich                 Cat\# D5030
  MEM/EBSS glutamine                                                                HyClone                       Cat\# SH30024.01
  MEM Nonessential Amino Acids                                                      Corning                       Cat\# 25025CL
  Glutagro                                                                          Corning                       Cat\# 25015CL
  Sodium Bicarbonate                                                                Corning                       Cat\# 25035CL
  Sodium Pyruvate                                                                   Corning                       Cat\# 25000CL
  FBS                                                                               VWR                           Cat\# 16000--044
  Charcoal stripped FBS                                                             Sigma-Aldrich                 Cat\# F6765
  Lipofectamine 2000                                                                Invitrogen                    Cat\# 11668019
  Trizol                                                                            Ambion                        Cat\# 15596018
  Glutaraldehyde                                                                    Polysciences, Inc.            Cat\# 01909
  RNase Out                                                                         Invitrogen                    Cat\# 10777019
  Formaldehyde                                                                      VWR                           Cat\# 0493
  Paraformaldehyde                                                                  Sigma-Aldrich                 Cat\# 158127
  Temsirolimus                                                                      Selleckchem                   Cat\# S1044
  Torin 1                                                                           Med Chem Express              Cat\# HY-13003
  7AAD                                                                              Tonbo                         Cat\# 13--6993-T500
  Optima LC-MS grade water                                                          Thermo Fisher Scientific      Cat\# W6--4
  Optima LC-MS grade acetonitrile                                                   Thermo Fisher Scientific      Cat\# A955--4
  Optima LC-MS grade methanol                                                       Thermo Fisher Scientific      Cat\# A456--4
  1,1,1,3,3,3-hexafluoro 2-propanol (HFIP)                                          Sigma-Aldrich                 Cat\# 105228
  Diisopropylethylamine (DIPEA)                                                     Sigma-Aldrich                 Cat\# D125806
  AMP standard                                                                      Sigma-Aldrich                 Cat\# 01930
  dAMP standard                                                                     Sigma-Aldrich                 Cat\# D6375
  ATP standard                                                                      Sigma-Aldrich                 Cat\# A26209
  dATP standard                                                                     Sigma-Aldrich                 Cat\# D6500
  dTMP standard                                                                     Sigma-Aldrich                 Cat\# T7004
  dTTP standard                                                                     Sigma-Aldrich                 Cat\# T0251
  CMP standard                                                                      Sigma-Aldrich                 Cat\# C1006
  dCMP standard                                                                     Sigma-Aldrich                 Cat\# D7625
  CTP standard                                                                      Sigma-Aldrich                 Cat\# C1506
  dCTP standard                                                                     Sigma-Aldrich                 Cat\# D4635
  UMP standard                                                                      Sigma-Aldrich                 Cat\# U6375
  dUMP standard                                                                     Sigma-Aldrich                 Cat\# D3876
  UDP standard                                                                      Sigma-Aldrich                 Cat\# 94330
  UTP standard                                                                      Sigma-Aldrich                 Cat\# U6625
  dUTP standard                                                                     Sigma-Aldrich                 Cat\# D4001
  AMP-^13^C,^15^N standard                                                          Sigma-Aldrich                 Cat\# 650676
  dAMP-^13^C,^15^N standard                                                         Sigma-Aldrich                 Cat\# 648620
  ATP-^13^C, ^15^N standard                                                         Sigma-Aldrich                 Cat\# 645702
  dATP-^13^C, ^15^N standard                                                        Sigma-Aldrich                 Cat\# 646237
  TTP-^13^C, ^15^N standard                                                         Sigma-Aldrich                 Cat\# 646202
  CTP-^13^C, ^15^N standard                                                         Sigma-Aldrich                 Cat\# 645699
  dTPC-^13^C, ^15^N standard                                                        Sigma-Aldrich                 Cat\# 646229
  UTP-^13^C, ^15^N standard                                                         Sigma-Aldrich                 Cat\# 645672
  dTMP-^13^C, ^15^N standard                                                        Sigma-Aldrich                 Cat\# 648590
  CMP-^13^C, ^15^N standard                                                         Sigma-Aldrich                 Cat\# 650692
  UMP-^13^C, ^15^N standard                                                         Sigma-Aldrich                 Cat\# 651370
                                                                                                                  
  Critical Commercial Assays                                                                                      
                                                                                                                  
  NucleoSpin RNA/Protein                                                            Macherey-Nagel                Cat\#740933
                                                                                                                  
  Deposited Data                                                                                                  
                                                                                                                  
  RNA-Seq                                                                           This paper                    GEO: GSE133660
                                                                                                                  
  Experimental Models: Cell Lines                                                                                 
                                                                                                                  
  Fibroblasts: IMR90                                                                ATCC                          CCL-186
  Fibroblasts: IMR90 shControl                                                      This paper                    N/A
  Fibroblasts: IMR90 shRRM2                                                         This paper                    N/A
  Fibroblasts: IMR90 shp16                                                          This paper                    N/A
  Fibroblasts: IMR90 shRRM2/shp16                                                   This paper                    N/A
  Fibroblasts: IMR90 shRRM2/shRB                                                    This paper                    N/A
  Fibroblasts: IMR90 shRPIA                                                         This paper                    N/A
  Fibroblasts: IMR90 shRRM2/shp16/shRPIA                                            This paper                    N/A
  Fibroblasts: IMR90 shRRM2/shp16/p16 OE                                            This paper                    N/A
  Fibroblasts: IMR90 Control                                                        This paper                    N/A
  Fibroblasts: IMR90 BRAF^V600E^                                                    This paper                    N/A
  Fibroblasts: IMR90 BRAF^V600E^/shp16                                              This paper                    N/A
  Fibroblasts: IMR90 BRAF^V600E^/shRB                                               This paper                    N/A
  BRAF^V600E^/shp16/shRPIA                                                          This paper                    N/A
  Embryonic kidney: 293FT                                                           Thermo Fisher                 R70007
  Embryonic kidney: Phoenix (QNX)                                                   Dr. Gary Nolan                N/A
  Skin: SKMel28                                                                     ATCC                          HTB-72
  Skin: SKMel28 shControl                                                           This paper                    N/A
  Skin: SKMel28 shRPIA                                                              This paper                    N/A
  Skin: SKMel28 shp16                                                               This paper                    N/A
  Skin: SKMel28 shp16/shRPIA                                                        This paper                    N/A
  Skin: SKMel28 shRB                                                                This paper                    N/A
  Skin: SKMel28: shp16/shRPTOR \#1                                                  This paper                    N/A
  Skin: SKMel28: shp16/shRPTOR \#2                                                  This paper                    N/A
  Pancreas: PATU8902                                                                G. DeNicola Laboratory        N/A
  Pancreas: PATU8902 shControl                                                      This paper                    N/A
  Pancreas: PATU8902 shRPIA                                                         This paper                    N/A
  Pancreas: PATU8902 shp16                                                          This paper                    N/A
  Pancreas: PATU8902 shp16/shRPIA                                                   This paper                    N/A
  Ovary: ES-2                                                                       ATCC                          Crl-1978
  Ovary: ES-2 shControl                                                             This paper                    N/A
  Ovary: ES-2 shRPIA                                                                This paper                    N/A
  Ovary: ES-2 shp16                                                                 This paper                    N/A
  Ovary: ES-2 shp16/shRPIA                                                          This paper                    N/A
  Bladder: TCC-SUP                                                                  ATCC                          HTB-5
  Bladder: TCC-SUP shControl                                                        This paper                    N/A
  Bladder: TCC-SUP shRPIA                                                           This paper                    N/A
  Bladder: TCC-SUP shp16                                                            This paper                    N/A
  Bladder: TCC-SUP shp16/shRPIA                                                     This paper                    N/A
  Colon: SW620                                                                      ATCC                          CCL-227
  Colon: SW620 shControl                                                            This paper                    N/A
  Colon: SW620 shRPIA                                                               This paper                    N/A
  Colon: SW620 shp16                                                                This paper                    N/A
  Colon: SW620 shp16/shRPIA                                                         This paper                    N/A
  Colon: SW480                                                                      ATCC                          CCL-228
  Colon: SW480 shControl                                                            This paper                    N/A
  Colon: SW480 shRPIA                                                               This paper                    N/A
  Colon: SW480 shp16                                                                This paper                    N/A
  Colon: SW480 shp16/shRPIA                                                         This paper                    N/A
  Colon: HT-29                                                                      ATCC                          HTB-38
  Colon: HT-29 shControl                                                            This paper                    N/A
  Colon: HT-29 shRPIA                                                               This paper                    N/A
  Colon: HT-29 shp16                                                                This paper                    N/A
  Colon: HT-29 shp16/shRPIA                                                         This paper                    N/A
  Skin: SKMel28 shRB                                                                This paper                    N/A
  Skin: SKMel28: shp16/shRPTOR \#1                                                  This paper                    N/A
  Skin: SKMel28: shp16/shRPTOR \#2                                                  This paper                    N/A
                                                                                                                  
  Experimental Models: Organisms/Strains                                                                          
                                                                                                                  
  C.B-17/ICRHsd-Prkdc scid mice                                                     Envigo                        182
                                                                                                                  
  Oligonucleotides                                                                                                
                                                                                                                  
  RT-qPCR Primers (Listed in [Table S2](#SD1){ref-type="supplementary-material"})   This paper                    N/A
                                                                                                                  
  Software and Algorithms                                                                                         
                                                                                                                  
  GSEA                                                                              Broad Institute               N/A
  GraphPad Prism 7                                                                  N/A                           N/A
  IDT tool for primer design                                                        Integrated DNA Technologies   N/A
  Cufflinks                                                                         Version v.2.0.2               N/A

###### Highlights

-   p16 knockdown activates mTORC1 to increase nucleotide synthesis and bypass senescence

-   mTORC1 directly increases translation of *RPIA* to increase ribose-5-phosphate

-   Activation of the mTORC1 pathway downstream of p16 suppression is independent of RB

-   RPIA suppression induces senescence only in cells and tumors with low p16
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